BioWorld

April 30, 2004

Cytokinetics IPO Raises $90M For Late-Stage Cancer Drugs

Cytokinetics Inc. priced its initial public offering Thursday, raising $89.7 million, slightly more than it expected to raise when it filed in January. (BioWorld Today) Read More

OrthoLogic Expanding Peptide Platform Via Chrysalis Buyout

Members Of Congress Petition Bush For ESC Policy Change

SkyePharma Divests Dermatology Assets, Sells Debt, Reports Loss

Other News To Note

Today's news in brief

BioWorld

BioWorld briefs for Dec. 12, 2025.

Today's news in brief

BioWorld MedTech

BioWorld MedTech briefs for Dec. 12, 2025.

CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials

BioWorld

A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...

Illustration of head with maze that is missing parts

CTAD 2025: The challenges of combination therapies for dementia

BioWorld Science

At the Clinical Trials on Alzheimer’s Disease 2025 meeting, a panel of experts discussed the need for developing combination therapies for the complex diseases...

DEE-lightful: Praxis’ phase II results allow stock to flex its muscle

BioWorld

Positive efficacy results led to Praxis Precision Medicines Inc.’s phase II Embold study in developmental and epileptic encephalopathies (DEEs) being halted...